Skip to main content

Table 5 Regression analysis of variables affecting change in CAARS:O-SV score (main analysis set)

From: Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial

 

Estimate

p-value

Difference in least squares means

p-value

Baseline

–0.4203

0.0007

Prior adherence

–0.0145

0.7530

Treatment group:

    

 54 mg

2.6840

0.7436

–2.7528

0.0145

 72 mg

12.2774

0.1441

–4.5799

< 0.0001

Baseline × Treatment group:

    

 54 mg

0.1473

0.3922

 72 mg

–0.2533

0.1448

Time point (versus Week 13)

    

 Week 1

3.9770

0.0003

7.1825

0.0001

 Week 3

1.8149

0.0767

3.3609

< 0.0001

 Week 5

1.5768

0.0923

2.8016

< 0.0001

 Week 7

–0.0884

0.9186

0.8591

0.1023

 Week 9

0.3289

0.6653

0.5197

0.2625

Time point × Treatment group

    

 Week 1 × 54 mg

4.6804

0.0037

0.3118

0.8088

 Week 1 × 72 mg

4.8763

0.0022

–1.6352

0.1917

 Week 3 × 54 mg

2.1269

0.1603

–2.2417

0.0908

 Week 3 × 72 mg

2.5112

0.0914

–4.0003

0.0020

 Week 5 × 54 mg

1.8791

0.1753

–2.4895

0.0667

 Week 5 × 72 mg

1.7954

0.1878

–4.7161

0.0004

 Week 7 × 54 mg

0.7517

0.5571

–3.6169

0.0101

 Week 7 × 72 mg

2.0907

0.0980

–4.4208

0.0013

 Week 9 × 54 mg

0.2565

0.8192

–4.1121

0.0045

 Week 9 × 72 mg

0.3160

0.7777

–6.1955

< 0.0001

Treatment group × adherence

    

 54 mg

–0.1276

0.0197

 72 mg

–0.0976

0.0721

Female sex

–1.5429

0.0949

No family history of ADHD

2.4018

0.0104

Time since ADHD diagnosis

0.1403

0.0072